|
|
Volumn 370, Issue 9588, 2007, Pages 643-644
|
|
Experts disagree over NICE's approach for assessing drugs.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CHOLINESTERASE INHIBITOR;
NOOTROPIC AGENT;
AGED;
ALZHEIMER DISEASE;
ARTICLE;
COST BENEFIT ANALYSIS;
ECONOMICS;
HEALTH CARE ORGANIZATION;
HUMAN;
LEGAL ASPECT;
QUALITY ADJUSTED LIFE YEAR;
UNITED KINGDOM;
AGED;
ALZHEIMER DISEASE;
CHOLINESTERASE INHIBITORS;
COST-BENEFIT ANALYSIS;
GREAT BRITAIN;
HEALTH CARE RATIONING;
HUMANS;
NOOTROPIC AGENTS;
QUALITY-ADJUSTED LIFE YEARS;
|
|
EID: 34548710231
PISSN: None
EISSN: 1474547X
Source Type: Journal
DOI: 10.1016/S0140-6736(07)61321-X Document Type: Article |
|
Times cited : (12)
|
|
References (0)
|
